L-Boronphenylalanine Biodistribution Dynamics in the Organs of Mice with Subcutaneous Tumor Xenograft is a Model to Assess Neuron Sources Efficiency in Boron Neutron Capture Therapy.

I N Druzkova, A A Pakhomova, N I Ignatova, A R Suleymanova, A V Maslennikova

Abstract read

In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

I N DruzkovaPhD, Researcher, Fluorescent Bioimaging Laboratory, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

A A PakhomovaStudent; National Research Lobachevsky State University of Nizhny Novgorod, 23 Prospekt Gagarina, Nizhny Novgorod, 603022, Russia.

N I IgnatovaPhD, Associate Professor, Department of Epidemiology, Microbiology and Evidence-Based Medicine; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

A R SuleymanovaStudent; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

A V MaslennikovaMD, DSc, Head of the Department of Oncology, Radiation Therapy and Radiology; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Boron neutron capture therapy (BNCT), due to its high biological efficiency, is one of the most promising methods of radiation therapy for malignant tumors. Currently, research in this area has received momentum due to the emergence of fundamentally new compact neutron sources suitable for clinical use. Materials and Methods: The experiments were carried out on BALB/c mice with subcutaneous xenograft of mouse adenocarcinoma CT26. L-boronphenylalanine in a molar excess of fructose was administered intravenously at a dose of 350 mg/kg, the organs under study were taken 1.5, 3, 6, and 24 h after drug administration. The content of the Results: The maximum L-BPA content in the tumor was 142.0±4.41 μg/g 1.5 h after drug administration. The minimum therapeutic concentration of L-BPA in the tumor persists up to 5.4 h after drug administration. Among normal organs, the maximum content was observed in the kidneys, it is most likely being associated with the structural and functional features of the organ rather than the true content of L-BPA in the tissues. Histological studies revealed no structural disorders and dystrophic changes in tissues against the background of L-BPA introduction. Conclusion: The results of the study demonstrate the feasibility of the studied tumor model to evaluate the efficiency of new neutron sources for BNCT. The L-borophenylalanine content in the tumor and the time of maintaining the minimum therapeutic concentration appeared to be sufficient for effective BNCT. The high contrast of

Indexed as

Boron Neutron Capture TherapyMice, Inbred BALB CAnimalsBoron CompoundsCell Line, TumorMicePhenylalanineTissue DistributionXenograft Model Antitumor Assays4-boronophenylalanineBoron CompoundsPhenylalaninebiodistributionboron neutron capture therapyinductively coupled plasma mass spectroscopyL-boronphenylalanineL-BPAradiation therapy

Identifiers

PMID39944369

DOI10.17691/stm2023.15.6.02

PMCPMC11811830

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.